Eli Lilly and Company (LLY) has launched 7.5 mg and 10 mg Zepbound single-dose vials for $499 under the Zepbound Self Pay Journey Program, making the obesity medication more affordable for self-pay patients. The 7.5 mg and 10 mg vials were previously priced at $599 and $699, respectively.
Zepbound is a dual GIP and GLP-1 receptor agonist, FDA-approved for the treatment of obesity, as well as for adults with moderate-to-severe obstructive sleep apnea and obesity.
The latest price reductions also apply to the 2.5 mg and 5 mg doses. The 2.5 mg dose has been reduced to $349 per month, while the 5 mg dose is now priced at $499 per month.
When Zepbound was initially launched in August 2024, the cost for a four-week supply of the 2.5 mg vial was $399 ($99.75 per vial), while a four-week supply of the 5 mg vial was priced at $549 ($137.25 per vial).
The Zepbound Self Pay Journey Program, which offers transparent pricing by eliminating third-party intermediaries, is designed to help patients access these treatments directly without relying on insurance coverage.
The recent price reductions represent Lilly's ongoing efforts to address the high cost of obesity care and provide more affordable treatment options for patients paying out of pocket.
Lilly's efforts are recognized by organizations like the Obesity Action Coalition or OAC, which commended the price reduction, while also calling for a healthcare system that ensures comprehensive care and coverage for individuals with obesity.
Currently, LLY is trading at $908.09 up by 0.70 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.